iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Purchased by Readystate Asset Management LP

Readystate Asset Management LP increased its stake in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 34.2% in the 4th quarter, HoldingsChannel reports. The firm owned 141,791 shares of the company’s stock after purchasing an additional 36,100 shares during the period. Readystate Asset Management LP’s holdings in iTeos Therapeutics were worth $1,553,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. American International Group Inc. grew its stake in iTeos Therapeutics by 7.7% during the 1st quarter. American International Group Inc. now owns 11,563 shares of the company’s stock worth $372,000 after purchasing an additional 830 shares in the last quarter. Silverarc Capital Management LLC lifted its holdings in iTeos Therapeutics by 0.6% during the 1st quarter. Silverarc Capital Management LLC now owns 138,843 shares of the company’s stock worth $4,468,000 after buying an additional 837 shares during the last quarter. Gladius Capital Management LP lifted its holdings in iTeos Therapeutics by 48.7% during the 4th quarter. Gladius Capital Management LP now owns 3,131 shares of the company’s stock worth $34,000 after buying an additional 1,026 shares during the last quarter. Royal Bank of Canada lifted its holdings in iTeos Therapeutics by 94.3% during the 2nd quarter. Royal Bank of Canada now owns 2,586 shares of the company’s stock worth $34,000 after buying an additional 1,255 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its holdings in iTeos Therapeutics by 131.5% during the 3rd quarter. PNC Financial Services Group Inc. now owns 2,287 shares of the company’s stock worth $25,000 after buying an additional 1,299 shares during the last quarter. 97.16% of the stock is owned by institutional investors and hedge funds.

iTeos Therapeutics Stock Performance

NASDAQ ITOS traded down $0.42 during trading on Wednesday, reaching $10.68. 198,768 shares of the company’s stock were exchanged, compared to its average volume of 269,485. The stock has a market cap of $382.77 million, a P/E ratio of -3.39 and a beta of 1.19. The company has a 50 day moving average price of $11.40 and a two-hundred day moving average price of $10.59. iTeos Therapeutics, Inc. has a 1 year low of $8.20 and a 1 year high of $18.24.

iTeos Therapeutics (NASDAQ:ITOS) last posted its earnings results on Wednesday, March 6th. The company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($1.03) by $0.18. Research analysts forecast that iTeos Therapeutics, Inc. will post -4.76 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have issued reports on ITOS shares. HC Wainwright reaffirmed a “buy” rating and set a $44.00 price target on shares of iTeos Therapeutics in a report on Thursday, March 7th. Wedbush reaffirmed an “outperform” rating and set a $18.00 price target (down from $25.00) on shares of iTeos Therapeutics in a report on Wednesday, March 6th.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.